← All Posts
SPR
ARS Pharmaceuticals, Inc.
June 25, 2026
•
Author: Phil Ratcliff
•
SPRY
| Item |
Proposal |
Vote |
| 1 |
To elect our Board of Directors' three nominees for Class III director named in the accompanying proxy statement to serve for three-year terms until the 2029 Annual Meeting of Stockholders. |
|
| 1.01 |
Saqib Islam, J.D. |
✓ For(34)
|
| 1.02 |
Phillip Schneider |
✓ For(34)
|
| 1.03 |
Laura Shawver, Ph.D. |
✓ For(34)
|
| 2 |
To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026. |
✓ For(34)
|
| 3 |
To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement. |
✓ For(34)
|
| 4 |
To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers. |
1 Year
|
| 5 |
To conduct any other business properly brought before the meeting. |
Informational(34)
|
This article was written for information purposes only and its content should not be
construed by any consumer and/or prospective client as rebel Financial's solicitation
to affect, or attempt to affect transactions in securities, or the rendering of
personalized investment advice for compensation. No client or prospective client should
assume that any such discussion serves as the receipt of, or a substitute for,
personalized advice from rebel Financial, or from any other investment professional.
See our disclosures page for more information.
rebel Financial